Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Thura Win Htut"'
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 43-47 (2022)
Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinic
Externí odkaz:
https://doaj.org/article/c0220c93af63480281ddf320b0d8004f
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 12 (2021)
Aims: Individuals taking immunosuppressants are at increased susceptibility to viral infections in general. However, due to the novel nature of the COVID-19, there is a lack of evidence about the specific risks of the disease in this patient group. T
Externí odkaz:
https://doaj.org/article/3427f334d3f34d8cba3e74f0321edd6a
Publikováno v:
Supportive Care in Cancer. 30:8511-8517
Thrombosis is the second leading cause of death in cancer patients. Patients with pancreatic cancer (PC) have a very high risk of developing venous thromboembolism (VTE). Even though primary ambulatory thromboprophylaxis (PATP) could decrease this ri
Publikováno v:
Proc (Bayl Univ Med Cent)
Ovarian cancer (OC) is highly associated with venous thromboembolism (VTE). The OC cells stimulate thrombin generation, and chemotherapy potentiates the prothrombotic effect of cancer cells by damaging endothelium and enhancing hypercoagulability. Re
Publikováno v:
Journal of Immunotherapy and Precision Oncology. 5:43-47
Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinic
Publikováno v:
Proc (Bayl Univ Med Cent)
Primary ambulatory thromboprophylaxis (PATP) in patients with solid malignancies is not routinely indicated. We performed a meta-analysis of randomized controlled trials (RCTs) to determine the benefit and risk of PATP in patients with nonpancreatic
Autor:
Kyaw Zin Thein, Thura Win Htut, Myat Min Han, Yin Mon Myat, Myint Aung Win, Ei Moe Phyu, Thein H. Oo
Publikováno v:
Blood. 140:10887-10888
Autor:
Kyaw Zin Thein, Thura Win Htut, Myat Min Han, Yin Mon Myat, Myint Aung Win, Ei Moe Phyu, Thein H. Oo
Publikováno v:
Blood. 140:7997-7998
Autor:
Matthew R. Wilson, Toby A. Eyre, Amy A. Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolás Martinez-Calle, Gavin Preston, Matthew Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L. Lewis, Teresa Calimeri, Eric Durot, Loïc Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Timothy J. Ebsworth, Johnathan Elliot, Anna Santarsieri, Laure Ricard, Nimish Shah, Qin Liu, Adam S. Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish Scott, Anna Guidetti, Brett R. Barlow, Emmanuelle Tchernonog, Jeffery Smith, Fiona Miall, Christopher P. Fox, Chan Y. Cheah, Tarec Christoffer El Galaly, Andrés J. M. Ferreri, Kate Cwynarski, Pamela McKay
Publikováno v:
Wilson, M R, Eyre, T A, Kirkwood, A A, Wong Doo, N, Soussain, C, Choquet, S, Martinez-Calle, N, Preston, G, Ahearne, M J, Schorb, E, Moles-Moreau, M-P, Ku, M, Rusconi, C, Khwaja, J, Narkhede, M, Lewis, K L, Calimeri, T, Durot, E, Renaud, L, Øvlisen, A K, Mcilroy, G, Ebsworth, T J, Elliot, J, Santarsieri, A, Ricard, L, Shah, N, Liu, Q, Zayac, A S, Vassallo, F, Lebras, L, Roulin, L, Lombion, N, Manos, K, Fernandez, R, Hamad, N, Lopez-Garcia, A, O'Mahony, D, Gounder, P, Forgeard, N, Lees, C, Agbetiafa, K, Strüessmann, T, Htut, T W, Clavert, A, Scott, H, Guidetti, A, Barlow, B R, Tchernonog, E, Smith, J, Miall, F, Fox, C P, Cheah, C Y, El Galaly, T C, Ferreri, A J M, Cwynarski, K & McKay, P 2022, ' Timing of high dose methotrexate CNS prophylaxis in DLBCL : a multicenter international analysis of 1,384 patients ', Blood, vol. 139, no. 16, pp. 2499-2511 . https://doi.org/10.1182/blood.2021014506
Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the optimal delivery method. We con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::906a66418f9b1bfafd3fd14b33943dce
https://vbn.aau.dk/da/publications/4c8d4993-b73b-4f50-a5d0-8e283e951137
https://vbn.aau.dk/da/publications/4c8d4993-b73b-4f50-a5d0-8e283e951137
Publikováno v:
British journal of haematologyReferences. 194(5)